M

Marinomed Biotech AG
VSE:MARI

Watchlist Manager
Marinomed Biotech AG
VSE:MARI
Watchlist
Price: 41.8 EUR 1.7% Market Closed
Market Cap: 20.6m EUR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+15%
Revenue
Forecast
+9%
Operating Income
Forecast
+11%
Net Income
Forecast
+14%

Wall Street
Price Targets

MARI Price Targets Summary
Marinomed Biotech AG

Wall Street analysts forecast MARI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MARI is 42.84 EUR with a low forecast of 42.42 EUR and a high forecast of 44.1 EUR.

MARI Lowest Forecast
Wall Street Target
42.42 EUR
1% Upside
MARI Average Forecast
Wall Street Target
42.84 EUR
2% Upside
MARI Highest Forecast
Wall Street Target
44.1 EUR
6% Upside
Lowest
Price Target
42.42 EUR
1% Upside
Average
Price Target
42.84 EUR
2% Upside
Highest
Price Target
44.1 EUR
6% Upside
Marinomed Biotech AG Competitors:
Price Targets
600216
Zhejiang Medicine Co Ltd
14% Upside
P
603566
Pulike Biological Engineering Inc
9% Upside
VENUSREM
Venus Remedies Ltd
27% Downside
600085
Beijing Tongrentang Co Ltd
26% Upside
600216
Zhejiang Medicine Co Ltd
14% Upside
P
603566
Pulike Biological Engineering Inc
9% Upside
VENUSREM
Venus Remedies Ltd
27% Downside
600085
Beijing Tongrentang Co Ltd
26% Upside
688526
Wuhan Keqian Biology Co Ltd
36% Upside

Revenue
Forecast

Revenue Estimate
Marinomed Biotech AG

For the last 6 years the compound annual growth rate for Marinomed Biotech AG's revenue is 11%. The projected CAGR for the next 3 years is -24%.

11%
Past Growth
-24%
Estimated Growth
Estimates Accuracy
-12%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Marinomed Biotech AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Marinomed Biotech AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
MARI intrinsic value, competitors valuation, and company profile.
DCF Valuation
MARI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MARI stock valuation using valuation multiples.
Wall Street Estimates
MARI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MARI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MARI's stock price target?
Price Target
42.84 EUR

According to Wall Street analysts, the average 1-year price target for MARI is 42.84 EUR with a low forecast of 42.42 EUR and a high forecast of 44.1 EUR.

What is Marinomed Biotech AG's Revenue forecast?
Projected CAGR
-24%

For the last 6 years the compound annual growth rate for Marinomed Biotech AG's revenue is 11%. The projected CAGR for the next 3 years is -24%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 267,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.